☆ 4.4 Article

Cardiovascular safety of zoledronic acid in the treatment of primary osteoporosis: A meta-analysis and systematic review

SEMINARS IN ARTHRITIS AND RHEUMATISM (2024)

Related references

Note: Only part of the references are listed.

Article Medicine, General & Internal

Pharmacologic Treatment of Primary Osteoporosis or Low Bone Mass to Prevent Fractures in Adults: A Living Clinical Guideline From the American College of Physicians

Amir Qaseem et al.

Summary: This guideline updates the 2017 ACP recommendations on pharmacologic treatment of primary osteoporosis or low bone mass. The recommendations include the use of bisphosphonates as initial treatment, the use of RANK ligand inhibitor as second-line treatment, and an individualized approach for starting pharmacologic treatment with bisphosphonates. Most recommendations are based on high-certainty evidence.

ANNALS OF INTERNAL MEDICINE (2023)

Add to Collection

Review Endocrinology & Metabolism

Global, regional prevalence, and risk factors of osteoporosis according to the World Health Organization diagnostic criteria: a systematic review and meta-analysis

P. -L. Xiao et al.

Summary: This systematic review and meta-analysis estimated the global and regional prevalence of osteoporosis and identified the risk factors associated with the disease. The study found significant variations in osteoporosis prevalence across different countries and regions, with higher rates observed in developing countries compared to developed countries.

OSTEOPOROSIS INTERNATIONAL (2022)

Add to Collection

Review Biochemistry & Molecular Biology

Current Status of the Diagnosis and Management of Osteoporosis

Agustin Aibar-Almazan et al.

Summary: Osteoporosis, a silent disease of the 21st century, poses a public health risk and mainly affects postmenopausal women and older adults. The disease is characterized by an imbalance between bone resorption and production. Treatments include pharmacological approaches using anti-resorptive drugs as well as non-pharmacological approaches focusing on lifestyle habits such as physical activity and diet.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Add to Collection

Article Endocrinology & Metabolism

Menopausal hormone therapy for the management of osteoporosis

Anna Gosset et al.

Summary: Postmenopausal osteoporosis is a common condition, and MHT can effectively prevent bone loss and reduce the risk of fractures. The individual benefit-risk balance of MHT should be considered based on personal risk profile, and MHT may be used as a first option for bone health maintenance in certain women.

BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Association between the cumulative exposure to bisphosphonates and hospitalization for atherosclerotic cardiovascular events: A population-based study

Manuela Casula et al.

ATHEROSCLEROSIS (2020)

Add to Collection

Review Pharmacology & Pharmacy

Assessment of Cardiovascular Safety of Anti-Osteoporosis Drugs

N. R. Fuggle et al.

DRUGS (2020)

Add to Collection

Article Medicine, General & Internal

Fracture Prevention with Zoledronate in Older Women with Osteopenia

Ian R. Reid et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Immunology

Zoledronic acid exacerbates inflammation through M1 macrophage polarization

Junya Kaneko et al.

INFLAMMATION AND REGENERATION (2018)

Add to Collection

Article Medicine, General & Internal

Excess mortality after hip fracture in elderly persons from Europe and the USA: the CHANCES project

M. Katsoulis et al.

JOURNAL OF INTERNAL MEDICINE (2017)

Add to Collection

Article Pharmacology & Pharmacy

Efficacy and Safety of Zoledronic Acid for Treatment of Postmenopausal Osteoporosis: A Meta-Analysis of Randomized Controlled Trials

Chao Wang

AMERICAN JOURNAL OF THERAPEUTICS (2017)

Add to Collection

Article Endocrinology & Metabolism

The Effect of 6 Versus 9 Years of Zoledronic Acid Treatment in Osteoporosis: A Randomized Second Extension to the HORIZON-Pivotal Fracture Trial (PFT)

Dennis M. Black et al.

JOURNAL OF BONE AND MINERAL RESEARCH (2015)

Add to Collection

Article Medicine, General & Internal

Efficacy and Safety of Single-Dose Zoledronic Acid for Osteoporosis in Frail Elderly Women A Randomized Clinical Trial

Susan L. Greenspan et al.

JAMA INTERNAL MEDICINE (2015)

Add to Collection

Review Economics

A Systematic Review of Cost-Effectiveness Analyses of Drugs for Postmenopausal Osteoporosis

Mickael Hiligsmann et al.

PHARMACOECONOMICS (2015)

Add to Collection

Article Multidisciplinary Sciences

Bisphosphonates and Risk of Cardiovascular Events: A Meta-Analysis

Dae Hyun Kim et al.

PLOS ONE (2015)

Add to Collection

Article Endocrinology & Metabolism

Markers of inflammation after zoledronic acid redosing

Antonis Sykiotis et al.

JOURNAL OF BONE AND MINERAL METABOLISM (2014)

Add to Collection

Article Endocrinology & Metabolism

The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)

Dennis M. Black et al.

JOURNAL OF BONE AND MINERAL RESEARCH (2012)

Add to Collection

Article Medicine, General & Internal

A functional variant in the promoter region regulates the C-reactive protein gene and is a potential candidate for increased risk of atrial fibrillation

S. -N. Chang et al.

JOURNAL OF INTERNAL MEDICINE (2012)

Add to Collection

Article Medicine, General & Internal

Fracture Risk and Zoledronic Acid Therapy in Men with Osteoporosis

Steven Boonen et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)

Add to Collection

Article Medicine, General & Internal

Hip Fracture and Increased Short-term but Not Long-term Mortality in Healthy Older Women

Erin S. LeBlanc et al.

ARCHIVES OF INTERNAL MEDICINE (2011)

Add to Collection

Article Oncology

Zoledronic acid and atrial fibrillation in cancer patients

Cagatay Arslan et al.

SUPPORTIVE CARE IN CANCER (2011)

Add to Collection

Review Cardiac & Cardiovascular Systems

Impact of Bisphosphonates on the Risk of Atrial Fibrillation

Patricia A. Howard et al.

AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS (2010)

Add to Collection

Review Cardiac & Cardiovascular Systems

Bisphosphonate use in women and the risk of atrial fibrillation: A systematic review and meta-analysis

Rohit Bhuriya et al.

INTERNATIONAL JOURNAL OF CARDIOLOGY (2010)

Add to Collection

Article Rheumatology

Osteoporosis and mortality

Ariane Leboime et al.

JOINT BONE SPINE (2010)

Add to Collection

Article Endocrinology & Metabolism

Atrial Fibrillation and Bisphosphonate Therapy

Michael Pazianas et al.

JOURNAL OF BONE AND MINERAL RESEARCH (2010)

Add to Collection

Article Rheumatology

Bisphosphonates and risk of atrial fibrillation: a meta-analysis

Seo Young Kim et al.

ARTHRITIS RESEARCH & THERAPY (2010)

Add to Collection

Article Orthopedics

Bisphosphonates and atrial fibrillation: Bayesian meta-analyses of randomized controlled trials and observational studies

Anselm Mak et al.

BMC MUSCULOSKELETAL DISORDERS (2009)

Add to Collection

Article Public, Environmental & Occupational Health

Bisphosphonates and Atrial Fibrillation Systematic Review and Meta-Analysis

Yoon Kong Loke et al.

DRUG SAFETY (2009)

Add to Collection

Article Medicine, General & Internal

Atrial fibrillation in fracture patients treated with oral bisphosphonates

B. Abrahamsen et al.

JOURNAL OF INTERNAL MEDICINE (2009)

Add to Collection

Article Obstetrics & Gynecology

Zoledronic Acid for the Prevention of Bone Loss in Postmenopausal Women With Low Bone Mass A Randomized Controlled Trial

Michael McClung et al.

OBSTETRICS AND GYNECOLOGY (2009)

Add to Collection

Article Medicine, General & Internal

Zoledronic acid and clinical fractures and mortality after hip fracture

Kenneth W. Lyles et al.

NEW ENGLAND JOURNAL OF MEDICINE (2007)

Add to Collection

© Peeref 2019-2024. All rights reserved.